<SEC-DOCUMENT>0000724910-25-000005.txt : 20250623
<SEC-HEADER>0000724910-25-000005.hdr.sgml : 20250623
<ACCEPTANCE-DATETIME>20250623162101
ACCESSION NUMBER:		0000724910-25-000005
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20250623
DATE AS OF CHANGE:		20250623

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NVE CORP /NEW/
		CENTRAL INDEX KEY:			0000724910
		STANDARD INDUSTRIAL CLASSIFICATION:	SEMICONDUCTORS & RELATED DEVICES [3674]
		ORGANIZATION NAME:           	04 Manufacturing
		EIN:				411424202
		STATE OF INCORPORATION:			MN
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-12196
		FILM NUMBER:		251065200

	BUSINESS ADDRESS:	
		STREET 1:		11409 VALLEY VIEW ROAD
		CITY:			EDEN PRAIRIE
		STATE:			MN
		ZIP:			55344
		BUSINESS PHONE:		9528299217

	MAIL ADDRESS:	
		STREET 1:		11409 VALLEY VIEW ROAD
		CITY:			EDEN PRAIRIE
		STATE:			MN
		ZIP:			55344

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PREMIS CORP
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>NVE_2025_Letter.htm
<DESCRIPTION>SHAREHOLDER LETTER
<TEXT>
<html>
<font style="font-size: 10pt; font-family: Times New Roman;">&nbsp;<br></font>
<hr style="margin-top: -5px; color: black;" noshade size="3">
<hr style="margin-top: -14px; color: black;" noshade size="1">
<div align="center"><font style="font-size: 5pt; font-family: Times New Roman;">&nbsp;<br></font>
<b><font face="Times New Roman" style="font-size:12pt;">UNITED
STATES<br>
SECURITIES AND EXCHANGE COMMISSION<br>
</font></b><font style="font-size: 10pt; font-family: Times New Roman;"><b>Washington,
D.C.&nbsp;&nbsp;20549<br>
</b></font><font style="font-size: 10pt; font-family: Times New Roman; line-height: 5pt;">_______________</font></div>
<p align="center"><b><font size="5" face="Times New Roman" style="font-size:12pt;">SCHEDULE
14A INFORMATION</font></b><br>
<div align="center"><font face="Times New Roman" style="font-size:10pt;">Proxy
Statement Pursuant to Section&nbsp;14(a)&nbsp;of the Securities Exchange Act of
1934<br>
(Amendment No.&nbsp;&nbsp;&nbsp;)<br>
</font></div>
<font face="Times New Roman" style="font-size:10pt;">Filed by the Registrant&nbsp;&nbsp;&#x2611;<br>
<div align="CENTER"></div>
Filed by a party other than the Registrant&nbsp;&nbsp;&#x2610;<br>
&nbsp; <br>
Check the appropriate box:</font>
<table style="font-size: 10pt; font-family: Times New Roman;" border="0" cellspacing="0" cellpadding="0" width="100%">
<tr>
<td width="18">&#x2610;</td>
<td>Preliminary Proxy Statement</td>
</tr>
<tr>
<td>&#x2610;</td>
<td>Confidential, for Use of the Commission Only (as permitted by Rule&nbsp;14a-6(e)(2))</td>
</tr>
<tr>
<td>&#x2610;</td>
<td>Definitive Proxy Statement</td>
</tr>
<tr>
<td>&#x2611;</td>
<td>Definitive Additional Materials</td>
</tr>
<tr>
<td>&#x2610;</td>
<td>Soliciting Material under &sect; 240.14a-12</td>
</tr>
</table>
<b><font face="Times New Roman" style="font-size:10pt;font-weight:bold;">&nbsp;</font></b>
<div align="center"><img src="nve-logo.gif" width="276" height="54" alt="NVE Logo"><font style="display: inline; font-size: 26pt; font-family: Arial;"><b><br>
NVE Corporation</b><br>
</font><font face="Times New Roman" style="font-size:10pt;">(Name of Registrant
as Specified In Its Charter)<br>
&nbsp;<br>
&nbsp;<br>
(Name of Person(s)&nbsp;Filing Proxy Statement, if other than the Registrant)<br>
&nbsp;<br>
</font></div>
<table style="font-size: 10pt; font-family: Times New Roman;" border="0" cellspacing="0" cellpadding="0" width="100%">
<tr>
<td colspan="3" valign="top">Payment of Filing Fee (Check all boxes that apply):</td>
</tr>
<tr>
<td width="18" valign="top">&#x2611;</td>
<td colspan="2" valign="top">No fee required.</td>
</tr>
<tr>
<td valign="top">&nbsp;</td>
<td colspan="2" valign="top">&nbsp;</td>
</tr>
<tr>
<td valign="top">&#x2610;</td>
<td colspan="2" valign="top">Fee paid previously with preliminary materials.</td>
</tr>
<tr>
<td valign="top">&nbsp;</td>
<td colspan="2" valign="top">&nbsp;</td>
</tr>
<tr>
<td valign="top">&#x2610;</td>
<td colspan="2" valign="top"> Fee computed on table in exhibit required by Item
25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11</td>
</tr>
<tr>
<td valign="top">&nbsp;</td>
<td colspan="2" valign="top">&nbsp;</td>
</tr>
<tr>
<td valign="top">&nbsp;</td>
<td colspan="2" valign="top">&nbsp;</td>
</tr>
<tr>
<td valign="top">&nbsp;</td>
<td colspan="2" valign="top">&nbsp;</td>
</tr>
<tr>
<td valign="top">&nbsp;</td>
<td colspan="2" valign="top">&nbsp;</td>
</tr>
</table>
<hr style="margin-top: -15px; color: black;" noshade size="3">
<div style="page-break-after: always;"><font face="Times New Roman, Times, serif" size="2">&nbsp;</font><br>
<div style="page-break-after: always;"> </div>
<hr color="#0046AD" noshade>
<table width="100%" border="0" cellspacing="00" cellpadding="0">
<tr>
<td><img src="sml-logo.gif" width="126" height="35" alt="Small NVE logo"></td>
<td>
<div align="right"><font face="Arial, Helvetica" style="font-size:8pt;">11409
Valley View Road<br>
Eden Prairie, MN 55344-3617 <br>
www.nve.com</font></div>
</td>
</tr>
</table>
<hr color="#0046AD" noshade><font style="font-size: 10pt" face="Arial, Helvetica, sans-serif">&nbsp;<br>
<b>Fellow Shareholders,</b></font><font style="font-size: 10pt" font-family: Times New Roman;"><br>
We continued strong earnings the past year and reported strong sequential growth
in the most recent quarter. We remain focused on developing innovative products
and promoting our products with trade shows, newsletters, evaluation kits, and
demonstration videos. We have invested in R&amp;D, new equipment, and inventories.
In the past year we completed an expansion to enable future growth.<br>
<br>
<b>Strong Earnings</b><br>
High-value products allowed us to weather industry weakness in the first three
quarters of the past fiscal year. We were pleased to report strong earnings for
fiscal 2025 despite a revenue decrease for the full year.<br>
<br>
<b>Product Innovation</b><br>
Our products acquire and transmit information and power. We develop technologies
for high-value market opportunities such as the industrial internet of things
and medical devices. Last year&#146;s product innovations included:<br>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;&nbsp;&nbsp;high-sensitivity ultraminiature
sensors;<br>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;&nbsp;&nbsp;a new type of rotation sensor;<br>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;&nbsp;&nbsp;our first wafer-level chip-scale
sensors;<br>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;&nbsp;&nbsp;advanced position sensors; and<br>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;&nbsp;&nbsp;new product evaluation boards.<br>
<br>
Please visit our website or <i>YouTube</i> channel for more information and demonstrations
of these unique products.<br>
<br>
<b>Medical Device Partnerships</b><br>
We are proud to partner with leading medical device suppliers on life-changing
devices that demand the highest quality and reliability, and in 2025, we extended
a partnering agreement with Abbott Laboratories.<br>
<br>
<b>R&amp;D for the Future</b><br>
R&amp;D expenditures increased 33% in the past fiscal year. These investments
will drive future growth. Medium-term product development programs the past year
included next-generation MRAM for antitamper applications, next-generation sensors
for medical devices, ultrahigh-sensitivity TMR sensors, next-generation sensors
for hearing aids and implanted medical devices, and wafer-level chip-scale devices.<br>
<br>
<b>Aggressive Expansion</b><br>
Construction for a multimillion-dollar expansion has been completed, and the investments
will increase our capacity and capabilities, including wafer-level chip-scale
manufacturing. Wafer-level chip-scale parts extend our market advantage as the
world&#146;s smallest devices of their type. These parts will also allow us to
be more self-sufficient and capture more value by eliminating the need for outsourced
packaging.<br>
<br>
<b>Enhancing Shareholder Value</b><br>
As reported in the accompanying proxy statement, your Total Shareholder Return
for the past three fiscal years was 39%. We remain committed to generous dividends
to enhance shareholder value, returning over $200 million&#151;more than $42&nbsp;per
share&#151;since we started paying dividends ten years ago.<br>
<br>
<b>Well Positioned</b><br>
High-value products, inventory investments, and unique self-sufficiency position
us to thrive in a fluid international trade environment. </font><font style="font-size: 10pt" font-family: Times New Roman;">The
stage </font><font style="font-size: 10pt" font-family: Times New Roman;">is set
</font><font style="font-size: 10pt" font-family: Times New Roman;">for renewed
growth.</font> <font style="font-size: 10pt" font-family: Times New Roman;">We
will begin reaping the benefits of our investments in capacity and product development</font><font style="font-size: 10pt" font-family: Times New Roman;">
in the coming year</font><font style="font-size: 10pt" font-family: Times New Roman;">.</font><font style="font-size: 10pt" font-family: Times New Roman;"><br>
<br>
Thank you for your support.<br>
Sincerely,<br>
&nbsp;<br>
<img src="dab-sig.gif" alt="-s- Daniel A. Baker" width="115" height="36" border="0"><br>
Daniel A. Baker<br>
President and Chief Executive Officer<br>
&nbsp;<br>
<i><b>Statements in this letter that relate to future plans, events, or performance
are forward-looking statements that are subject to certain risks and uncertainties
including the risk factors listed from time to time in our filings with the SEC,
including our Annual Report on Form 10-K for the fiscal year ended March&nbsp;31, 2025.
Actual results could differ materially from the information provided, and we undertake
no obligation to update forward-looking statements.</b></i></font><br>
</div>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>nve-logo.gif
<DESCRIPTION>NVE LOGO
<TEXT>
begin 644 nve-logo.gif
M1TE&.#EA% $V +,   !&K0DW>0<C3$!.8GAY>O___^+BXK2TM
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MU_)%,+*=NCKJ)0UAF'57%7FR*J/NBF^\WLZ/K&KJ\K?1?<FQJM(7'2>Z\>A
M6Z^^U0$_=_9@A?J,2]0S^5?G[KV)=W.\!X[1Z>$OZ23KAVSY.J+<@R6\);7?
<W_[PN0-QO@E!Z%WBFM(PQNEH$ 9,H %1$P$ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>sml-logo.gif
<DESCRIPTION>SMALL NVE LOGO
<TEXT>
begin 644 sml-logo.gif
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MP0.=J_S+O#OSO42O_B=^+=4H3XJEB1(W[;T]<\(#"NH6Z)4[_>1WMR?^&=>
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<A2=TP-80,)$81NB #PPX80-&",/][+ \ 0$ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>dab-sig.gif
<DESCRIPTION>DANIEL A. BAKER SIGNATURE
<TEXT>
begin 644 dab-sig.gif
M1TE&.#EA<P D +,   $! 0L+"Q<7%R<G)S<W-T]/3V=G9W=W=X>'AYB8F*^O
MK\?'Q]W=W?#P\/____O[^RP     <P D   (_@ ="!Q(L*!!@0P4(%B8H,'!
MAQ C2IQ(L:+%@@T2% @ 0 "! @0 !&!PL:3)DR@E-C@@ $"!!"0',A!@(.5
MAS8?,C 0,Z?%E0$$'.A9$&1. P1\&FS0<H%2B@T0!""@X$'$ @)L,N@H,<$
M!1<+  ! %"*#!"D?)!#PU6K$!@%JICP ("G$!6,%X)R(=ZQ;B5)1,B @(,$#
M! 4D&B";DJE+B(['.IWXX&.! 17%[K6(P*7#K6 A*@ @%^5B  @@+@X)8'+7
MU@,.4'S \2]4L0C<)@A@N^#, 9M+XN7HNB!> G1;\YV*M_A= G8K,A@@H'B!
MQ \;$ C@_&*# =!Y_A^LW!HZXX@S6QO 3-&  NP4%P@00)1!@- &'XC%?]+
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<DM?FH\NGO 67* 'F4XP5-U\:\Y@IX=<# @( .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
